The world’s first new crown vaccine application landscape report released

The world's first new crown vaccine application landscape report released

On July 29, the “Global New Crown Vaccine Application Vision Report” (in Chinese and English), completed by the Boao Forum for Asia Research Institute and the Chongyang Institute of Finance of Renmin University of China, was released. And prospects, showing the full picture of the new crown vaccine application from a global perspective. The report was released by Li Baodong, Secretary-General of the Boao Forum for Asia, and Wang Wen, Executive Dean of the Chongyang Institute of Finance of Renmin University of China (Chongyang), introduced the specific content of the report. The conference invited representatives of many international organizations, envoys of relevant countries to China, and experts in the field of vaccines to participate in the conference.

Since the beginning of 2020, the outbreak of the novel coronavirus (COVID-19) has spread worldwide, causing the most serious global public health crisis in a century. By mid-2021, the epidemic is still raging around the world. As of July 20, 2021, there were a total of 190,671,330 confirmed cases of new coronary pneumonia worldwide and a total of 4,098,758 deaths. The new crown vaccine that has been accelerated in the severe epidemic has shown good effects against the virus and has become the main means of controlling the spread of the epidemic. As of July 20, 2021, 3.7 billion doses of the new crown vaccine have been vaccinated globally, and 26.5% of the world’s population have received at least one dose of the new crown vaccine. At least 209 countries and regions have begun to promote vaccination, but vaccination in various countries and regions is at different stages, and vaccination is showing a serious international imbalance. In order to better promote the prevention and control of the global epidemic, this report graphically shows the full picture of the application of the new crown vaccine from a global perspective and gives suggestions for promoting the effective prevention and control of the new crown epidemic on a global scale and its early end.

The report mainly collects data related to the new crown vaccine through websites such as the World Health Organization and COVID-19 Vaccine Tracker, and tracks the current status of global new crown vaccine candidates and vaccine research and development in trials.

The report pointed out that compared with the development process of other infectious disease vaccines in history, the new crown vaccine is one of the fastest developed infectious disease vaccines in human history. Despite the accelerated development mode, the safety of the vaccine has also been effectively guaranteed.

China and other emerging economies have once again joined the ranks of emergency vaccine research and development. This is a remarkable change. The report’s research has drawn the key to ending the new crown epidemic globally as soon as possible. Although the mutation of the virus has brought challenges to the effectiveness of the vaccine, the vaccine is still an effective way to defend against the new coronavirus. How long the global new crown epidemic will continue depends largely on whether the development and distribution of vaccines can keep up with the speed of the virus’s spread and mutation. The total production capacity of the global new crown vaccine is expected to basically meet the needs of realizing global herd immunity by the end of 2021. The question is whether the production capacity of the vaccine can be in place as scheduled and whether it can be distributed fairly and reasonably globally. The number of vaccination in China is far ahead in the world. On June 19, 2021, China’s vaccination will exceed 1 billion doses, which is more than 1/3 of the global vaccination number. It is expected to complete at least 70% of the target population by the end of 2021. Vaccination. Western developed countries generally lead in vaccination rates, but have not yet fully reached the herd immunity threshold. Among the countries with a population of more than 30% in the whole course of vaccination, European and American countries account for the majority. The United States originally planned to achieve the goal of 70% of the nation’s adult population receiving at least one dose of the new crown vaccine by July 4, 2021, but this goal has not been achieved, and 30% of American adults are still hesitating or refusing to get the vaccine. As of July 19, 2021, more than 60% of people in Canada, the United Kingdom, Spain, and Italy have been partially vaccinated against the new crown vaccine, and more than 50% of people in Germany, France, the United States, and Saudi Arabia have been partially vaccinated against the new crown vaccine. The vaccination rate in Japan is much lower than that of developed countries in Europe and America, and it lags behind in vaccine development.

The most prominent problem facing the international community in the fight against the epidemic is how to improve the accessibility and affordability of vaccines in developing countries. As long as the “immune gap” between underdeveloped countries and developed countries still exists, and some countries in the world have not reached the herd immunity threshold, the world will still face public health risks. A large number of facts and data show that major countries have insufficient action on the international distribution of vaccines. The United States is hoarding a large number of vaccines. There is a large gap between the actual number of vaccines provided to the outside world and its capacity. In fact, only less than 24 million doses were shipped abroad.

Exports account for less than one percent of US vaccine production, and millions of excess doses of the epidemic have been discarded due to expiration. By this summer, 300 million or more vaccines may be surplus.

The main goal of EU countries is to ensure the vaccination rate within the EU member states, while exports are mainly to middle- and high-income countries. More than 522 million doses of vaccines are allocated to the EU and European Economic Area countries. The Group of Seven (G7) summit pledged to donate 1 billion doses of new crown vaccine to poor countries by the end of 2022, but this is still far from the global demand for vaccines.